Hosted on MSN
Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results
Merck & Co., Inc. (NYSE:MRK) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback